Patents Assigned to Boehringer Ingelheim International GmbH
-
Patent number: 11851418Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein R, R1, A1, A2, L1, and L2 are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are methods of using the compounds of formula (I) for treatment of diseases, which can be influenced by inhibition of plasma kallikrein.Type: GrantFiled: February 11, 2021Date of Patent: December 26, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Matthias Eckhardt, Maude Giroud, Camilla Mayer, Holger Wagner, Dieter Wiedenmayer
-
Patent number: 11851495Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.Type: GrantFiled: October 30, 2020Date of Patent: December 26, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
-
Patent number: 11833166Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (CKD).Type: GrantFiled: June 10, 2021Date of Patent: December 5, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Uli Christian Broedl, Sreeraj Macha, Maximilian von Eynatten, Hans-Juergen Woerle
-
Patent number: 11813266Abstract: The application refers to a novel combination treatment/combination medicament for PF-ILD treatment, comprising as a first combination partner a therapeutically effective amount of Nintedanib or a pharmaceutically acceptable salt thereof and as a second combination partner a therapeutically effective amount of a PDE4B-inhibitor of formula I wherein Ring A is a 6-membered aromatic ring which may optionally comprise one or two nitrogen atoms and wherein R is Cl and wherein R may be located either in the para-, meta- or ortho-position of Ring A, wherein S* is a sulphur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. Hereby the second combination partner is preferably a therapeutically effective amount of the PDE4B-inhibitior of formula III or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 12, 2022Date of Patent: November 14, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Franziska Elena Herrmann, Peter Nickolaus, Stefan Ludwig Michael Wollin
-
Patent number: 11814380Abstract: The present invention encompasses compounds of formula (1) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.Type: GrantFiled: September 24, 2020Date of Patent: November 14, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Juergen Ramharter, Christiane Kofink, Heinz Stadtmueller, Tobias Wunberg, Marco Hans Hofmann, Anke Baum, Michael Gmachl, Dorothea Ingrid Rudolph, Fabio Savarese, Markus Ostermeier, Markus Frank, Annika Gille, Stefan Goepper, Marco Santagostino, Julian Wippich
-
Patent number: 11813312Abstract: The present invention relates to the medical use of specific long-acting glucagon analogues having dual GLP-1/glucagon receptor agonist activity in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), NAFLD-associated liver fibrosis and/or cirrhosis.Type: GrantFiled: April 22, 2021Date of Patent: November 14, 2023Assignee: Boehringer Ingelheim International GmbHInventor: Leo Thomas
-
Patent number: 11813275Abstract: The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.Type: GrantFiled: July 21, 2021Date of Patent: November 14, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Uli Christian Broedl, Odd-Erik Johansen, Gabriel Woojai Kim, Eric Williams Mayoux, Afshin Salsali, Nima Soleymanlou, Maximilian von Eynatten, Hans-Juergen Woerle, David Z.I. Cherney, Bruce A. Perkins, Andreas Daiber, Thomas Muenzel
-
Patent number: 11795147Abstract: The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)Type: GrantFiled: August 26, 2020Date of Patent: October 24, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Kai Gerlach, Christian Eickmeier, Jan Magnus Kriegl, Lothar Kussmaul, Klaus Rudolf, Bernhard Schmid
-
Patent number: 11795219Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: May 11, 2020Date of Patent: October 24, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Walter Carroll Davidson, Pankaj Gupta, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Jr., Haiguang Xiao, Danlin Yang
-
Patent number: 11780827Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.Type: GrantFiled: March 29, 2021Date of Patent: October 10, 2023Assignees: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.Inventors: Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
-
Patent number: 11771848Abstract: A reservoir for a nebulizer includes: a tank or bag containing multiple doses of a fluid to be nebulized, and an indicator device for counting or indicating a number of uses performed or still possible with the reservoir, where at least one of: the reservoir includes a connector for fluidically connecting the tank or bag with the nebulizer, the indicator device is actuated by moving the connector relative to the tank or bag, and the reservoir includes or forms an eccentrical linear guidance for a driving part for driving the indicator device.Type: GrantFiled: December 9, 2021Date of Patent: October 3, 2023Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Joachim Carl Herbert Eicher, Alfred Von Schuckmann
-
Patent number: 11766443Abstract: The invention relates to cyclopentathiophene carboxamides of formula (I.0) wherein R1, R2, R3, R4, and n are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to the use of the cyclopentathiophene carboxamides of formula (I.0) for the treatment of diseases which can be influenced by antagonizing the activity mediated by the platelet activating factor receptor.Type: GrantFiled: November 12, 2021Date of Patent: September 26, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Matthias Eckhardt, Marina Kristina Willwacher, Juergen Prestle, Ferenc Kontes, Leo Thomas, Christofer Siegfried Tautermann, Dieter Wiedenmayer
-
Patent number: 11760745Abstract: Disclosed are heteroaromatic carboxamides of formula (I), wherein Y, R, and Ar are as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are the use of the compounds of formula (i) for the treatment of diseases which can be influenced by the inhibition of plasma kallikrein.Type: GrantFiled: February 11, 2021Date of Patent: September 19, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Matthias Eckhardt, Maude Giroud, Elke Langkopf, Camilla Mayer, Holger Wagner, Dieter Wiedenmayer
-
Publication number: 20230286946Abstract: The present invention relates to difluoromethyl-pyridin-2-yl triazoles of general formula (I) which are modulators of GABAA receptors containing the ?5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for the manufacture of compounds according to the invention.Type: ApplicationFiled: August 4, 2021Publication date: September 14, 2023Applicant: Boehringer Ingelheim International GmbHInventors: Florian Montel, Yunhai Cui, Niklas Heine, Oliver Hucke, Radoslaw Lipinski, Stefan Peters, Janus Schreiber Larsen
-
Publication number: 20230277783Abstract: A nebulizer for nebulizing a fluid is proposed. The nebulizer includes an indicator device with a rotatable indicator element for counting or indicating a number of actuations performed or still possible with the nebulizer and a rotatable shaft which rotatably drives the indicator element. The indicator device is non-detachably attached to the shaft and/or to an inner part of the nebulizer. The nebulizer may further include a positioning device that keeps the shaft in a defined rotational position and/or blocks the shaft from rotating backwards.Type: ApplicationFiled: June 30, 2021Publication date: September 7, 2023Applicant: Boehringer Ingelheim International GmbHInventor: Frank HERRMANN
-
Publication number: 20230265203Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.Type: ApplicationFiled: October 7, 2022Publication date: August 24, 2023Applicant: Boehringer Ingelheim International GmbHInventors: Scott Ronald BRODEUR, Thomas B. FREEMAN, Gerald Henry Nabozny, Meera RAMANUJAM, Paul SCHOLL, Juergen STEFFGEN
-
Patent number: 11732045Abstract: The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.Type: GrantFiled: October 1, 2020Date of Patent: August 22, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Susanne Hipp, Paul Adam, Michael Dziegelewski, Rajkumar Ganesan, Philip Nicholas Gorman, Pankaj Gupta, Priyanka Gupta, Marcio Lasaro, Justin M. Scheer, Vladimir H. Voynov
-
Patent number: 11730812Abstract: The present invention relates to anti-interleukin-36 receptor (anti-IL-36R1) antibody formulations for administration to a subject.Type: GrantFiled: March 5, 2020Date of Patent: August 22, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Sandra Nicole Denkinger, Anna Maria Steiner, Derrick Spencer Katayama, Rajni Prasad Mehra, Ingo Michael Presser, Ravija Singh, Sara Kay Wright
-
Patent number: 11725191Abstract: Methods for continuously inactivating virus during manufacture of a biological product are provided. The methods include steps of (1) combining (a) a composition including a biological product, and (b) a composition including a virus-inactivation reagent, to obtain (c) a treatment composition having a predetermined property for inactivation of a virus, (2) confirming that the treatment composition exhibits the predetermined property, (3) transferring the treatment composition to a treatment vessel that includes an inlet, an outlet, and a static mixer, the transferring occurring at the inlet, (4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows at a predetermined rate and contacts the static mixer, and (5) collecting the treatment composition from the treatment vessel at the outlet, wherein steps (1) to (5) are carried out continuously. Apparatuses and systems including such a treatment vessel are also provided.Type: GrantFiled: August 23, 2019Date of Patent: August 15, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Jonathan Coffman, Jeff Goby, Scott Godfrey, Raquel Orozco, Jens Holger Vogel
-
Patent number: RE49699Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: May 28, 2021Date of Patent: October 17, 2023Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLCInventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu